Abstract: Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for administration. Further, dispersion of Imatinib solid oral dosage forms may not administer correct and consistent dose of medicine every time. The present invention therefore provides liquid dosage forms of Imatinib which correctly and consistently administers correct dose of drug to the patients.

Abstract: Systems, devices, and methods for collimating a neutron beam to specified deliverable formats having targeted beam diameters and direction are described. Examples of a neutron collimator assembly can include numerous components based on location, function, dimension, and/or constituent material. The components can include, neutron beam collimators, a beam stop, a mounting assembly, electro-mechanical actuators, an electronic controller, a safety interlock system, a moveable radiation shield, a safety cover, and an adjustable patient platform. In addition, examples of variable aperture neutron beam collimators such as nested neutron beam collimators and collimators with a diaphragm iris are described. Materials are also described.

Abstract: An armrest assembly comprising a secondary armrest assembly is disclosed that can be deployed from a stowed and nested position beneath a primary armrest, with the secondary armrest assembly comprising a plurality of articulable and pivotable components, a seating assembly comprising the present armrest assembly, and vehicles configured to comprise the present armrest and seating assembly.

Abstract: Described herein are examples of a computerized method that comprises: in response to obtaining information regarding a potential collision between a vehicle and an object, obtaining data describing the vehicle for a time period extending before and after a time of the potential collision. The method may determine a likelihood that the potential collision is a non-collision event based on the data describing the vehicle by performing one or more assessments. The assessments may include telematics monitor assessment, driver behavior assessment, road surface feature assessment, trip correlation assessment, and/or context assessment. In response to determining that the likelihood indicates that the potential collision is not a non-collision event, the method may trigger one or more actions responding to the potential collision.

Abstract: Described herein are various techniques, including systems and non-transitory instructions, that, in response to obtaining information regarding a potential collision between a vehicle and an object, obtain data describing the vehicle for a time period extending before and after a time of the potential collision. The system may determine a likelihood that the potential collision is a non-collision event based on the data describing the vehicle by performing one or more assessments. The assessments may include telematics monitor assessment, driver behavior assessment, road surface feature assessment, trip correlation assessment, and/or context assessment. In response to determining that the likelihood indicates that the potential collision is not a non-collision event, the system may trigger one or more actions responding to the potential collision.

Abstract: Described herein are examples of a computerized method that comprises: in response to obtaining information regarding a potential collision between a vehicle and an object, obtaining data describing the vehicle for a time period extending before and after a time of the potential collision. The method may determine a likelihood that the potential collision is a non-collision event based on the data describing the vehicle by performing one or more assessments. The assessments may include telematics monitor assessment, driver behavior assessment, road surface feature assessment, trip correlation assessment, and/or context assessment. In response to determining that the likelihood indicates that the potential collision is not a non-collision event, the method may trigger one or more actions responding to the potential collision.

Abstract: Pharmaceutical compositions comprising a vehicle, a solubilizer, and a surfactant are disclosed to be used in conjunction with non-chemotherapeutic active pharmaceutical ingredients which are soluble in water but subject to hydrolysis to some extent. Such non-chemotherapeutic active pharmaceutical ingredients may include amitriptyline, a derivative thereof, or a combination thereof. The pharmaceutical compositions may be administered as an oral solution. Other embodiments are directed towards methods of using and methods of making such formulations.

Abstract: Embodiments of systems, devices, and methods relate to controlling beams for use in beam systems. An example method of controlling a travel path of a beam includes propagating a beam along a first path from an entry point of a dipole magnet through a non-gradient portion of the dipole magnet until the beam bends toward a first beam travel path of multiple beam travel paths of the dipole magnet. The example method further includes propagating the beam along the first beam travel path through a gradient portion of the dipole magnet to focus the beam for propagation to a downstream target. Embodiments further permit a compact beam system such that a series of magnets can be used to create a path that accommodates shielding to minimize the footprint of the beam system for facilities that may not otherwise support large systems due to space and safety constraints.

Abstract: Pharmaceutical compositions comprising oil as a vehicle, a suspending agent, and a surfactant are disclosed to be used in conjunction with active pharmaceutical ingredients which are water soluble or insoluble, or which are sensitive to water but insoluble in oil. Such active pharmaceutical ingredients may include temozolomide, lenalidomide, Oxaliplatin, Cisplatin, Carboplatin, 5-fluorouracil, irinotecan, topotecan, cyclophosphamide, doxorubicin, vincristine, vinblastine, Melphalan, Chlorambucil, Dacarbazine, Daunorubicin, Epirubicin, Mitoxantrone, Etoposide, Teniposide, Azacitidine, Cytarabine, Gemcitabine, vinoralbine, Pemetrexed, a derivative thereof, or a combination thereof. The pharmaceutical compositions may be administered as an oral suspension. Other embodiments are directed towards methods of using and methods of making such formulations.

Abstract: Pharmaceutical compositions comprising a vehicle, a solubilizer, and a surfactant are disclosed to be used in conjunction with non-chemotherapeutic active pharmaceutical ingredients which are soluble in water but subject to hydrolysis to some extent. Such non-chemotherapeutic active pharmaceutical ingredients may include amitriptyline, a derivative thereof, or a combination thereof. The pharmaceutical compositions may be administered as an oral solution. Other embodiments are directed towards methods of using and methods of making such formulations.

Abstract: Described herein are various techniques, including systems and non-transitory instructions, that, in response to obtaining information regarding a potential collision between a vehicle and an object, obtain data describing the vehicle for a time period extending before and after a time of the potential collision. The system may determine a likelihood that the potential collision is a non-collision event based on the data describing the vehicle by performing one or more assessments. The assessments may include telematics monitor assessment, driver behavior assessment, road surface feature assessment, trip correlation assessment, and/or context assessment. In response to determining that the likelihood indicates that the potential collision is not a non-collision event, the system may trigger one or more actions responding to the potential collision.

Abstract: Described herein are examples of a computerized method that comprises: in response to obtaining information regarding a potential collision between a vehicle and an object, obtaining data describing the vehicle for a time period extending before and after a time of the potential collision. The method may determine a likelihood that the potential collision is a non-collision event based on the data describing the vehicle by performing one or more assessments. The assessments may include telematics monitor assessment, driver behavior assessment, road surface feature assessment, trip correlation assessment, and/or context assessment. In response to determining that the likelihood indicates that the potential collision is not a non-collision event, the method may trigger one or more actions responding to the potential collision.

Abstract: Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for administration. Further, dispersion of Imatinib solid oral dosage forms may not administer correct and consistent dose of medicine every time. The present invention therefore provides liquid dosage forms of Imatinib which correctly and consistently administers correct dose of drug to the patients.

Abstract: Embodiments are provided relating to the exchange of devices or assemblies holding targets used in a beam system. With these embodiments a used target can be rapidly and safely replaced with a new target to permit continued operation in a clinical or other environment. Also provided are embodiments of valves having relatively lower profiles that facilitate engagement and disengagement of beamline sections for access to the target device or assembly. All or a portion of the valve can be part of the target assembly. Also provided are embodiments of storage containers for storing a volatile object, such as an object comprising a composition sensitive to atmospheric air and/or an object that is radioactive. The storage container can include a two-part shell case assembly configured for housing a volatile object between the two parts, which engage one another to form an air-tight seal therebetween.

Abstract: Systems and methods in accordance with various embodiments of the present disclosure provide secure handling of messages at a hardware-protocol level using a logic device on a server. Various embodiments provide approaches for filtering messages on various buses, such as SSIF, SMBus, PMBus, I2C, and SPI, within a server or a computer. Embodiments may include a policy engine through which message handling logic applied to a given bus or buses may be implemented. A message is compared to one or more policies. The message is allowed to be transmitted to a baseboard management controller based on the one or more policies and a type of message.

Abstract: Power systems and methods for supplying direct current power to a server rack via a power shelf assembly that includes multiple power supply units (PSUs) and a power shelf controller (PSC) that ensures a correct configuration of PSUs, backup battery units (BBUs), and connection components using a power shelf configuration record. Upon a boot cycle of the PSC, the configuration identified in the power shelf controller is compared to an actual configuration of the components being connected between a server rack and the power shelf assembly to avoid providing power too soon and causing an overload of components for the server rack.

Abstract: Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for administration. Further, dispersion of Imatinib solid oral dosage forms may not administer correct and consistent dose of medicine every time. The present invention therefore provides liquid dosage forms of Imatinib which correctly and consistently administers correct dose of drug to the patients.

Abstract: An assembly for containing and detecting leaks from a coolant line includes a basin with side and end walls, and at least one U-shaped cavity in an end wall for receiving a coolant line of a liquid cooling system. A bottom of the basin includes at least one sloped interior surface arranged to divert water in the basin to a local low point, where a sensor is positioned and operable to detect liquid in the collection basin. A leak detection system can employ a leak detection assembly to detect and/or locate a leak.

Abstract: The present invention discloses a processes for the preparation of a stable liquid pharmaceutical composition comprising levothyroxine or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients wherein the liquid composition of the present invention is used for oral administration. The present invention also discloses stable liquid compositions comprising levothyroxine or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients prepared according to the processes of the present invention.

Abstract: Systems and methods in accordance with various embodiments of the present disclosure provide secure handling of messages at a hardware-protocol level using a logic device on a server. Various embodiments provide approaches for filtering messages on various buses, such as SSIF, SMBus, PMBus, I2C, and SPI, within a server or a computer. Embodiments may include a policy engine through which message handling logic applied to a given bus or buses may be implemented. A message is compared to one or more policies. The message is allowed to be transmitted to a baseboard management controller based on the one or more policies and a type of message.